PL1879572T3 - Zastosowanie antagonistów oksytocyny i/lub wazopresyny we wspomaganym rozrodzie - Google Patents

Zastosowanie antagonistów oksytocyny i/lub wazopresyny we wspomaganym rozrodzie

Info

Publication number: PL1879572T3
Authority: PL; Poland
Prior art keywords: oxytocin; antagonists; vasopressin; medicament; manufacture
Prior art date: 2005-05-10

Application number

PL06747719T

Other languages

English (en)

Inventor

Waldemar Kuczyński

Piotr Pierzyński

Original Assignee

Ferring Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-10

Filing date

2006-05-10

Publication date

2011-10-31

2005-05-10 Priority claimed from PL374954A external-priority patent/PL374954A1/pl

2005-08-12 Priority claimed from PL376607A external-priority patent/PL376607A1/pl

2006-05-10 Application filed by Ferring Bv filed Critical Ferring Bv

2011-10-31 Publication of PL1879572T3 publication Critical patent/PL1879572T3/pl

Links

XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title abstract 4
239000005557 antagonist Substances 0.000 title abstract 4
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title abstract 4
229960001723 oxytocin Drugs 0.000 title abstract 4
101800000989 Oxytocin Proteins 0.000 title abstract 3
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title abstract 3
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 title abstract 3
108010004977 Vasopressins Proteins 0.000 title abstract 3
102000002852 Vasopressins Human genes 0.000 title abstract 3
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 title abstract 3
229960003726 vasopressin Drugs 0.000 title abstract 3
239000003814 drug Substances 0.000 abstract 3
238000004519 manufacturing process Methods 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
102000004279 Oxytocin receptors Human genes 0.000 abstract 1
108090000876 Oxytocin receptors Proteins 0.000 abstract 1
102000004136 Vasopressin Receptors Human genes 0.000 abstract 1
108090000643 Vasopressin Receptors Proteins 0.000 abstract 1
230000037020 contractile activity Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
230000009027 insemination Effects 0.000 abstract 1
210000001161 mammalian embryo Anatomy 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
210000004291 uterus Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

PL06747719T 2005-05-10 2006-05-10 Zastosowanie antagonistów oksytocyny i/lub wazopresyny we wspomaganym rozrodzie PL1879572T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
PL374954A PL374954A1 (pl)	2005-05-10	2005-05-10	Zastosowanie antagonistów oksytocyny lub antagonistów oksytocyny i wazopresyny lub antagonistów wazopresyny do wytwarzania leków stosowanych podczas procedur wspomaganego rozrodu
PL376607A PL376607A1 (pl)	2005-08-12	2005-08-12	Zastosowanie antagonistów oksytocyny i/lub wazopresyny
US73391605P	2005-11-04	2005-11-04
EP06747719A EP1879572B1 (en)	2005-05-10	2006-05-10	Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
PCT/PL2006/000029 WO2006121362A2 (en)	2005-05-10	2006-05-10	Use of antagonists of oxytocin and/or vasopressin in assisted reproduction

Publications (1)

Publication Number	Publication Date
PL1879572T3 true PL1879572T3 (pl)	2011-10-31

Family

ID=37056586

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06747719T PL1879572T3 (pl)	2005-05-10	2006-05-10	Zastosowanie antagonistów oksytocyny i/lub wazopresyny we wspomaganym rozrodzie

Country Status (20)

Country	Link
US (1)	US20080318847A1 (pl)
EP (1)	EP1879572B1 (pl)
JP (1)	JP4762308B2 (pl)
KR (1)	KR100985449B1 (pl)
CN (1)	CN101646436B (pl)
AT (1)	ATE507830T1 (pl)
AU (1)	AU2006244693B2 (pl)
CA (1)	CA2605923C (pl)
DE (1)	DE602006021736D1 (pl)
DK (1)	DK1879572T3 (pl)
ES (1)	ES2366130T3 (pl)
IL (1)	IL186595A (pl)
MX (1)	MX2007014022A (pl)
NO (1)	NO340956B1 (pl)
NZ (1)	NZ562409A (pl)
PL (1)	PL1879572T3 (pl)
PT (1)	PT1879572E (pl)
RU (1)	RU2385735C2 (pl)
SI (1)	SI1879572T1 (pl)
WO (1)	WO2006121362A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103417475B (zh) *	2013-06-27	2015-06-17	深圳翰宇药业股份有限公司	一种巴鲁西班注射液及其制备方法
EP2845850A1 (en)	2013-09-10	2015-03-11	ObsEva S.A.	Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) *	2013-12-17	2015-06-24	ObsEva S.A.	Oral formulations of pyrrolydine derivatives
KR102470283B1 (ko)	2014-07-02	2022-11-23	옵스에파 에스에이	결정질 (3z,5s)-5-(하이드록시메틸)-1-[(2'-메틸-1,1'-바이페닐-4-일)카르보닐]피롤리딘-3-온 o-메틸옥심
PL3037101T3 (pl) *	2014-12-22	2019-06-28	Ferring B.V.	Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu
CA3031252A1 (en) *	2016-07-21	2018-01-25	ObsEva S.A.	Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
JP7584201B2 (ja) *	2019-09-03	2024-11-15	オブセヴァエス．エー．	薬学的組成物
US20220395511A1 (en) *	2021-06-10	2022-12-15	Washington University	Compositions and methods for increasing cell surface oxytocin receptor (oxtr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US962413A (en) *	1909-05-13	1910-06-28	George Hillard Benjamin	Method of soldering chains.
US5948762A (en) *	1993-07-16	1999-09-07	Schering Aktiengesellschaft	Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
US5599809A (en) *	1994-09-29	1997-02-04	Merck & Co., Inc.	Method for improving reproductive efficiency in farm animals
US20010056068A1 (en) *	1998-03-04	2001-12-27	Kristof Chwalisz	Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
FR2807038B1 (fr) *	2000-04-03	2002-08-16	Sanofi Synthelabo	Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant

2006
- 2006-05-10 WO PCT/PL2006/000029 patent/WO2006121362A2/en not_active Ceased
- 2006-05-10 PT PT06747719T patent/PT1879572E/pt unknown
- 2006-05-10 KR KR1020077025706A patent/KR100985449B1/ko not_active Expired - Fee Related
- 2006-05-10 RU RU2007140702/15A patent/RU2385735C2/ru active
- 2006-05-10 DK DK06747719.0T patent/DK1879572T3/da active
- 2006-05-10 PL PL06747719T patent/PL1879572T3/pl unknown
- 2006-05-10 ES ES06747719T patent/ES2366130T3/es active Active
- 2006-05-10 MX MX2007014022A patent/MX2007014022A/es active IP Right Grant
- 2006-05-10 SI SI200631039T patent/SI1879572T1/sl unknown
- 2006-05-10 AT AT06747719T patent/ATE507830T1/de active
- 2006-05-10 EP EP06747719A patent/EP1879572B1/en active Active
- 2006-05-10 DE DE602006021736T patent/DE602006021736D1/de active Active
- 2006-05-10 AU AU2006244693A patent/AU2006244693B2/en not_active Ceased
- 2006-05-10 NZ NZ562409A patent/NZ562409A/en not_active IP Right Cessation
- 2006-05-10 CA CA2605923A patent/CA2605923C/en not_active Expired - Fee Related
- 2006-05-10 US US11/914,049 patent/US20080318847A1/en not_active Abandoned
- 2006-05-10 JP JP2008511075A patent/JP4762308B2/ja not_active Expired - Fee Related
- 2006-05-10 CN CN2006800568367A patent/CN101646436B/zh not_active Expired - Fee Related
2007
- 2007-10-11 IL IL186595A patent/IL186595A/en active IP Right Grant
- 2007-12-10 NO NO20076328A patent/NO340956B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ562409A (en)	2011-02-25
CN101646436A (zh)	2010-02-10
JP2008540519A (ja)	2008-11-20
PT1879572E (pt)	2011-08-23
DK1879572T3 (da)	2011-07-04
WO2006121362A3 (en)	2007-05-03
IL186595A (en)	2013-10-31
CN101646436B (zh)	2012-07-18
RU2007140702A (ru)	2009-06-20
WO2006121362A2 (en)	2006-11-16
ATE507830T1 (de)	2011-05-15
JP4762308B2 (ja)	2011-08-31
NO340956B1 (no)	2017-07-31
KR20070118186A (ko)	2007-12-13
EP1879572B1 (en)	2011-05-04
KR100985449B1 (ko)	2010-10-05
DE602006021736D1 (de)	2011-06-16
CA2605923A1 (en)	2006-11-16
NO20076328L (no)	2007-12-10
IL186595A0 (en)	2008-01-20
US20080318847A1 (en)	2008-12-25
AU2006244693A1 (en)	2006-11-16
SI1879572T1 (sl)	2011-07-29
CA2605923C (en)	2012-07-24
MX2007014022A (es)	2008-02-07
RU2385735C2 (ru)	2010-04-10
EP1879572A2 (en)	2008-01-23
ES2366130T3 (es)	2011-10-17
AU2006244693B2 (en)	2010-11-04

Publication	Publication Date	Title
IL186595A0 (en)	2008-01-20	Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
JOP20200222A1 (ar)	2022-10-30	أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
JOP20200277B1 (ar)	2024-04-18	مركبات تثبيط rip1 وطرق لتحضير واستخدامها
MX2021002322A (es)	2021-04-28	Nuevos metodos.
BR112013003677A2 (pt)	2016-09-06	uso de agente farmacologicamente ativo e forma de dosagem farmacêutica
MX2009006823A (es)	2009-07-03	Formas de dosificacion solidas de desintegracion oral que comprenden progestina y metodos para hacer y usar las mismas.
BRPI0511660A (pt)	2008-01-02	combinação, produto, kit de partes, embalagem, uso de um antagonista de receptores muscarìnicos m3 e de um agonista beta2, e, método para tratar um paciente sofrendo de ou suscetìvel a uma doença ou condição respiratória que responde ao antagonismo m3
MX2010009447A (es)	2010-09-24	Uso de antagonistas de lhrh a dosis no castrantes.
MX360148B (es)	2018-10-24	Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos.
EA201792595A1 (ru)	2018-06-29	Контрацептивное средство на основе дроспиренона для пациентки, страдающей избыточной массой тела
PH12020551911A1 (en)	2021-06-14	Use of riluzole oral disintigrating tablets for treating diseases
MX2020013157A (es)	2021-04-29	Métodos de tratamiento de afecciones relacionadas con el receptor s1p1.
MX2024007642A (es)	2024-07-04	Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
BR112019002513A2 (pt)	2019-05-14	uso e dosagem de agentes terapêuticos para endometriose
MX2024013184A (es)	2024-12-06	Metodos y composiciones para tratar apnea del sue?o
BR112015012497A2 (pt)	2017-07-11	combinações farmacêuticas
HK1113088A (en)	2008-09-26	Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
CL2015003014A1 (es)	2016-04-15	Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
BR112022012246A2 (pt)	2022-08-30	Uso de lemborexant para tratar insônia
CL2008003823A1 (es)	2010-01-22	Composicion farmaceutica para administracion oral que comprende 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-pirrol-2,5-diona o una sal y 2,5-12% de un lubricante definido; proceso de preparacion; util para tratar trastornos o enfermedades mediadas por linfocitos t y/o proteina quinasa c.
EA200970788A1 (ru)	2010-04-30	Применение vegf в лечении замедленного роста плода при беременности
NZ801872A (en)	2024-08-30	Managing moderate to severe pain associated with endometriosis in patients classified as child-pugh b
AR076016A1 (es)	2011-05-11	Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria
UA52334U (ru)	2010-08-25	Фармацевтическая композиция на основе парацетамола и диклофенака натрия
UA48739U (ru)	2010-03-25	СПОСОБ ЛЕЧЕНИЯ ОСТРЫХ РЕСПИРАТОРНЫХ ЗАБОЛЕВАНИЙ У ТЕЛЯТ\|телят\|